Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: Technical report and follow up of 21 patients

Voss, Pit Jacob; Oshero, J. Joshi; Kovalova-Müller, Alice; Merino, Egle Alina Veigel; Sauerbier, Sebastian; Al-Jamali, Jamil; Lemound, Juliana; Metzger, Marc Christian; Schmelzeisen, Rainer

doi:10.1016/j.jcms.2012.01.005

Cited by 103 publications

(69 citation statements)

References 49 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reported success rates vary considerably, including approximately 12-100% 16) , 54% of 33 patients 17) , and 23% of 29 patients 18) . However, comparisons of different studies are limited by the fact that different criteria may be used to define the success of treatment outcomes.…”

Section: Histological Evaluationmentioning

confidence: 99%

A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw

Sukegawa

Kanno

Kawai

et al. 2016

J. Hard Tissue Biology.

View full text Add to dashboard Cite

In 2014, the American Association of Oral and Maxillofacial Surgery recommended surgical treatment for medication-related osteonecrosis of the jaw (MRONJ) patients classified as stage 3 or those with mobile segments of bony sequestrum. However, there is limited information regarding the healing mechanism in MRONJ surgical treatments. This study aimed to retrospectively elucidate clinical outcomes of the surgical treatment of MRONJ patients. This study included 26 patients (7 men, 19 women; age: 42-92 years; mean ± standard deviation, 75.3 ± 11.7 years) who were classified as stage 3 or had mobile segments of bony sequestrum, and intake of the offending drug was ceased. The sequestrum was removed with surrounding vital bone, and segmental resection was performed in one patient with a pathological mandibular fracture. The outcome was classified into one of the following three categories: "Healing," "Improvement," "Unchanged." and "Exacerbation." The mean postoperative follow-up period was 16.6 months (3.0 -57.9 months), and complete healing was observed in 21 patients (80.8%), improvement of the lesion was observed in four patients (15.4%), and the outcome of one patient was unchanged (3.8%). The procedure described here may be recommended with relatively high clinical success rate for the patients with MRONJ requiring surgical treatment.

show abstract

Section: Histological Evaluationmentioning

confidence: 99%

A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw

Sukegawa

Kanno

Kawai

et al. 2016

J. Hard Tissue Biology.

View full text Add to dashboard Cite

show abstract

“…In letteratura è stata adottata una terminologia standardizzata per ONJ (per esempio resezione marginale e segmentale) [60,76], mentre c'è una minore chiarezza terminologica in merito ai trattamenti chirurgici conservativi. È stata recentemente proall'estensione della malattia, suggerendo la procedura di assegnazione sulla base del dato di imaging radiologico mediante Medicina orale tra osso normale e patologico è più spesso basato sull'idenmargini dell'osso ischemico (punto di sanguinamento) [77,78].…”

Section: > Ossigenoterapia Iperbaricaunclassified

Osteonecrosi dei mascellari associata a bisfosfonati, denosumab e farmaci anti-angiogenetici nei pazienti oncologici e osteoporotici: diagnosi e terapia

et al. 2013

View full text Add to dashboard Cite

RIASSUNTO ObiettiviONJ, OsteoNecrosis of the Jaws). Materiali e metodi. Gli autori del lavoro, recentemente estensori e collaboratori -su mandato della Società Italiana di Chirurgia Maxillo-Facciale (SICMF) e della Società Italiana di Patologia e Medicina Orale (SIPMO), delle Raccomandazioni clinico-terapeutiche sull'osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione -hanno e/o anti-angiogenetici, e revisionato l'epidemiologia, i fattori di rischio, la clinica e i criteri diagnostici. Vengono proposti protocolli di prevenzione primaria e secondaria, di management odontoiatrico e terapia della ONJ sia per il paziente oncologico sia per il paziente non oncologico, principalmente osteoporotico. Risultati e conclusioni. L'osteonecrosi delle ossa mascellari da bisfosfonati, ma anche, negli ultimi anni, da denosumab e anti-angiogenetici, si può considerare la più emergente delle patologie odontoiatriche severe: negli ultimi 10 anni si sono registrati migliaia di casi in letteratura, con importanti implicazioni sulla qualità di vita del paziente. La comunità medica e odontoiatrica ha percepito in questi anni la severità della patologia, ma anche la necessità di darsi regole e ridisegnare il percorso preventivo e assistenziale di tale malattia: in tutte le nazioni industrializzate, e parimenti in Italia, sono state stilate linee guida o raccomandazioni per la prevenzione e cura della ONJ, malattia inizialmente

show abstract

“…These difficulties have led several research teams to explore new therapeutic strategies for treatment and prevention of BRONJ disease. Mucosal coverage of alveolar sockets after dental extractions has been performed as treatment (Voss et al, 2012) and as a preventive measure (Abtahi et al, 2013) in order to avoid bacterial contamination and to increase blood supply to BP-affected bone during the healing process. Defective bone healing occurs in BRONJ because of suppressed bone turnover, likely favored by the antiangiogenic properties of potent BPs such as zoledronic acid (ZA) Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model a b s t r a c t Objectives: The main challenge in treating bisphosphonate-related osteonecrosis of the jaw (BRONJ) is the absence of an effective established treatment.…”

Section: Introductionmentioning

confidence: 99%

“…In order to not interfere with the immunological properties of the studied treatments (PRP and ASCs) and to allow us to better analyze the results without confounding factors, no other drugs were used (e.g., corticoids) to increase BRONJ incidence. Some authors defend the use of local flaps, especially for resistant cases, in advanced stages of disease (Williamson, 2010;Voss et al, 2012), or for preventive reasons (Abtahi et al, 2013). For our experimental study, we chose a mucoperiosteal flap as a standard local preventive treatment after dental extractions.…”

Section: Introductionmentioning

confidence: 99%

Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model

Barba-Recreo

Vera

Georgiev-Hristov

et al. 2015

Journal of Cranio-Maxillofacial Surgery

View full text Add to dashboard Cite

show abstract

Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: Technical report and follow up of 21 patients

Cited by 103 publications

References 49 publications

A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw

A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw

Osteonecrosi dei mascellari associata a bisfosfonati, denosumab e farmaci anti-angiogenetici nei pazienti oncologici e osteoporotici: diagnosi e terapia

Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model

Contact Info

Product

Resources

About